The citation gap: why some MedTech companies get quoted, and others get ignored
Whenever there's a development in NHS procurement, a NICE appraisal, or a piece of health technology innovation, the same handful of companies dominate the news coverage. The same names appear in the trade press, and the same spokespeople are quoted in the nationals and referenced in procurement briefings. This is a structural issue, and it's one we know all too well from our own healthcare PR and marketing work with UK MedTech firms. We also know that, for burgeoning companies trying to establish name recognition in these conditions, breaking through can feel like a hopeless endeavour.
However, giving up on communications would be a mistake. In a market of 4,360 MedTech companies (ABHI Written Evidence to Parliament, 2026), being quoted by a health correspondent or mentioned in a trade editorial signals authority over competitors, and because citation builds name recognition, and name recognition builds further citation, the advantage tends to snowball.
What "publishing more than pitching" actually looks like in practice
A common mistake we see among MedTech communications teams is treating product announcements and funding rounds as their primary, and sometimes only, contact point with the media. Although these moments may feel newsworthy on an internal level, a strategy that focuses too heavily on marketing ultimately produces diminishing returns. Journalists habituate to seeing press releases land in their inbox, and procurement audiences, who are looking for insight rather than announcements, turn elsewhere.
An insight-led approach produces markedly better results. According to the Edelman-LinkedIn B2B Thought Leadership Impact Report (2025), 95% of "hidden buyers" (those with final sign-off on group purchasing decisions but no deep sector expertise) say consistent thought leadership increases their receptiveness to sales and advertising outreach.
In practice, an insight-led publishing model involves:
- Regular commentary in peer-reviewed trade titles
- Proactive contributions to policy consultations
- LinkedIn articles from named clinical or commercial leads
- Timely responses to emerging regulatory or NHS structural developments
Quantity and cadence matter as much as quality when it comes to building an effective communications strategy. A single placement will do little to generate citation equity on its own. Instead, the most successful MedTech companies maintain a consistent rhythm across the above channels. This doesn't mean they simply produce more marketing material; instead, they actively earn audience trust by maintaining a clear distinction between editorial insight and product promotion.
The editorial behaviours that drive citation and commercial credibility
A common misconception among MedTech companies who have previously dabbled with thought leadership and returned underwhelming results is that the fault lies with opinion content in general. Our experience suggests a different culprit. Operating in the media landscape has taught us that the real roadblock can almost always be traced to the client's internal editorial procedure, not a lack of interest among journalists or clinical audiences.
MedTech credibility is scrutinised differently to most B2B sectors. If market language and clinical claims become blurred, there is a risk that it will actively damage trust or even pose a compliance risk to the company. As a result, internal governance must be ironed out before starting a publishing programme: who is writing the content (ideally a clinical or commercial lead), and who signs it off (regulatory and legal departments)?
Bylined commentary carries more weight than branded content, and journalists attribute more credibility to people than to brand logos. This is part of the reason that you see the same names consistently dominate the news cycle; journalists operating on tight deadlines already trust they are authoritative.
MedTech companies will be familiar with the evidentiary standards required by the NICE manual: unpublished evidence submitted to a technology hearing must meet the same criteria as published evidence and identify bias points before they come up in practice (NICE Technology Appraisal and Highly Specialised Technologies Guidance, 2026). The same principle is applicable to bylined thought leadership.
Broadcast communications on radio or TV are a natural next step for those who have built a public-facing image over time, and it's a good choice for companies with the budget to invest consistently rather than sporadically. In our experience with broadcast PR, named individuals who have an established body of work, as well as a public-facing image, are best positioned to secure media coverage.
Why MedTech thought leadership is a regulatory and commercial asset, not just a PR tactic
It's tempting to classify thought leadership as a communications tactic and leave it there. However, for MedTech companies operating in both public and private markets, the purpose extends beyond the obvious media benefits. Maintaining a published body of opinion content has a material effect on procurement outcomes, as well as regulatory standing.
Procurement teams in NHS integrated care systems and private hospital groups often treat a company's publishing record as informal due diligence; thus, a visible history of commentary can reduce objections at the tender stage and shorten the sales cycle in a way that advertising cannot.
Evidence from Edelman and LinkedIn backs this up: 79% of hidden decision-makers say they are more likely to advocate for companies that consistently produce high-quality thought leadership during the RFP process, highlighting the direct link between published opinion and inclusion in procurement conversations (Edelman-LinkedIn B2B Thought Leadership Impact Report, 2025).
Regulatory credibility is a related but separate benefit. Companies that have contributed to policy consultations and similar activity are better positioned to engage with regulators or commissioners down the line. The NICE manual notes that its commercial liaison team helps companies understand the evaluation process and works with NHS England and NHS Supply Chain to share information in support of commercial planning (NICE Technology Appraisal and Highly Specialised Technologies Guidance, 2026).
Thought leadership should be thought of as a compounding asset: each piece of commentary adds to a body of work that is searchable and citeable. This is different in structure to campaign-based PR, which defaults back to zero after activation. Our B2B PR work shows that this compounding effect is what divides companies with lasting credibility from those that are left to chase coverage after every product launch.
How to build a publishing programme that earns coverage rather than chasing it
The most effective publishing programmes distinguish between reactive and proactive output. Reactive commentary responds to press releases or relevant guidance, whereas proactive commentary is benchmarked against a publishing schedule linked to the company's own activities, independent of the news cycle.
The mix that works well for MedTech companies includes peer-reviewed trade titles, policy submissions and consultation responses, LinkedIn articles from named individuals, and broadcast media for spokespeople with an established profile.
However, this does not work without a named internal lead or external partner to claim ownership; publishing programmes will stall after the first quarter, once the initial momentum fades and day-to-day priorities take over.
Where to start: the practical first steps for UK MedTech teams
Not all MedTech companies have a large communications team or a mature content operation, and the publishing strategy should reflect this. The sensible starting point is therefore an audit: what are the company's clinical and commercial leads already saying internally, in board papers and conference talks? And which of this material can be adapted into external publishing content?
Scope should then be narrowed to two or three channels rather than overstretching. For growth-stage companies, this could mean one trade title, one or two named LinkedIn contributors, or a policy consultation response per quarter.
If the capacity to sign off thought leadership does not exist, the company must build it internally, or work with an external partner who can bring understanding of the clinical context and editorial standards required. This is the gap our startup PR work aims to fill for early-stage MedTech companies operating on a budget.
Companies that start building a publishing programme now will have a compounding body of work within 12 to 18 months. Their competitors, still relying on product announcements and funding round press releases, will be slow to catch up.
